Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Mayne Pharma Drug Patent Portfolio

Mayne Pharma owns 11 orange book drugs protected by 84 US patents with Doryx having the least patent protection, holding only 2 patents. And Bijuva with maximum patent protection, holding 24 patents. Given below is the list of Mayne Pharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10918649 System for providing birth control 21 Jun, 2039
Active
US10925882 System for providing birth control 21 Jun, 2039
Active
US10940157 System for providing birth control 21 Jun, 2039
Active
US11529308 System for providing birth control 21 Jun, 2039
Active
US11850251 System for providing birth control 21 Jun, 2039
Active
US10632066 Method of providing birth control 01 Feb, 2039
Active
US10765628 Method of providing birth control 01 Feb, 2039
Active
US10780047 Method of providing birth control 01 Feb, 2039
Active
US10857159 Halobetasol foam composition and method of use thereof 30 May, 2037
Active
US10857159 Halobetasol foam composition and method of use thereof 30 Nov, 2036
Active
US11020407 Corticosteroid containing foam compositions and method of manufacture thereof 30 Nov, 2036
Active
US11793760 Orodispersible dosage unit containing an estetrol component 17 Jun, 2036
Active
US11957694 Orodispersible dosage unit containing an estetrol component 17 Jun, 2036
Active
US11964055 Orodispersible dosage unit containing an estetrol component 17 Jun, 2036
Active
US10335391 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
Active
US10751325 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
Active
US11517560 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
Active
US9974773 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
Active
US9446057 Controlled release doxycycline 23 Dec, 2034
Active
US9295652 Controlled release doxycycline 23 Oct, 2034
Active
US9511031 Controlled release doxycycline 23 Oct, 2034
Active
US11266661 Vaginal inserted estradiol pharmaceutical compositions and methods 02 Feb, 2034
Active
US10258630 Vaginal inserted estradiol pharmaceutical compositions and methods 20 Dec, 2033
Active
US10398708 Vaginal inserted estradiol pharmaceutical compositions and methods 20 Dec, 2033
Active
US9180091 Soluble estradiol capsule for vaginal insertion 20 Dec, 2033
Active
US10463740 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
Active
US10806792 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
Active
US8921374 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
Active
US9272046 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
Active
US9713642 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
Active
US10471072 Vaginal inserted estradiol pharmaceutical compositions and methods 18 Jun, 2033
Active
US10568891 Vaginal inserted estradiol pharmaceutical compositions and methods 18 Jun, 2033
Active
US10668082 Vaginal inserted estradiol pharmaceutical compositions and methods 18 Jun, 2033
Active
US10888516 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
Active
US11065197 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
Active
US11116717 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
Active
US11123283 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
Active
US10052386 Progesterone formulations 21 Nov, 2032
Active
US10206932 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US10639375 Progesterone formulations 21 Nov, 2032
Active
US10675288 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US10806740 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11033626 Progesterone formulations having a desirable pk profile 21 Nov, 2032
Active
US11103513 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11103516 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11110099 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11166963 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11529360 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11793819 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US11865179 Progesterone formulations having a desirable PK profile 21 Nov, 2032
Active
US8633178 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US8846648 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US8846649 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US8933059 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US8987237 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US8993548 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US8993549 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US9006222 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US9114145 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US9114146 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US9301920 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
Active
US10537581 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US10806697 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US10835487 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US11241445 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US11246875 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US11304959 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US11351182 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US11497709 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US9289382 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
Active
US8883838 Pharmaceutical cream compositions and methods of use 01 Dec, 2031
Active
US10568859 Topical foam composition 24 Feb, 2030
Active
US10688071 Topical foam composition 24 Feb, 2030
Active
US8808716 Topical foam composition 24 Feb, 2030
Active
US8263580 Vitamin formulation 07 May, 2028
Active
US7812049 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists 02 May, 2028
Active
US8715724 Tabletting process 03 Feb, 2028
Active
US8269128 Vacuum switch tube 26 May, 2026
Active
US8629128 Vitamin formulation 26 May, 2026
Active
US7732430 Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception 02 Mar, 2025
Active
US8420688 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists 02 Aug, 2024 Expired
US8815929 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists 22 Jan, 2024 Expired
US8771739 Pharmaceutical compositions for poorly soluble drugs 25 Jul, 2023 Expired
US6958161 Modified release coated drug preparation 15 Dec, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Mayne Pharma.

Activity Date Patent Number
Patent litigations
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US11123283
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US11116717
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US10537581
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Jul, 2024 US10537581
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Jul, 2024 US9289382
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Jul, 2024 US10806697
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US11497709
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US10806697
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Jul, 2024 US11266661
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US9289382
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US11266661
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US10668082
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Jul, 2024 US10668082
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 17 Jul, 2024 US11304959
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 17 Jul, 2024 US10568891


Mayne Pharma's Drug Patent Litigations

Mayne Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 28, 2014, against patent number US10568859. The petitioner , challenged the validity of this patent, with Leon LOUPENOK as the respondent. Click below to track the latest information on how companies are challenging Mayne Pharma's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10688071 February, 2015 Decision
(14 Jul, 2017)
Leon LOUPENOK
US10568859 April, 2014 Decision
(21 Dec, 2016)
Leon LOUPENOK


Mayne Pharma Drug Patents' Oppositions Filed in EPO

Mayne Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 23, 2019, by Rieck, Markus. This opposition was filed on patent number EP13807121A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19163006A Sep, 2022 Dr. Schön, Neymeyr & Partner Patentanwälte mbB Granted and Under Opposition
EP19163006A Sep, 2022 Rieck, Markus Granted and Under Opposition
EP12850845A Mar, 2022 Generics [UK] Limited Granted and Under Opposition
EP12850845A Mar, 2022 Dr. Schön, Neymeyr & Partner Patentanwälte mbB Granted and Under Opposition
EP12850845A Mar, 2022 Rieck, Markus Granted and Under Opposition
EP13807188A Jan, 2022 Rieck, Markus Revoked
EP13807121A Dec, 2019 Rieck, Markus Revoked


Mayne Pharma's Family Patents

Mayne Pharma drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 34.9% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Mayne Pharma Drug List

Given below is the complete list of Mayne Pharma's drugs and the patents protecting them.


1. Annovera

Annovera is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10918649 System for providing birth control 21 Jun, 2039
(14 years from now)
Active
US10925882 System for providing birth control 21 Jun, 2039
(14 years from now)
Active
US10940157 System for providing birth control 21 Jun, 2039
(14 years from now)
Active
US11529308 System for providing birth control 21 Jun, 2039
(14 years from now)
Active
US11850251 System for providing birth control 21 Jun, 2039
(14 years from now)
Active
US10632066 Method of providing birth control 01 Feb, 2039
(14 years from now)
Active
US10765628 Method of providing birth control 01 Feb, 2039
(14 years from now)
Active
US10780047 Method of providing birth control 01 Feb, 2039
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Annovera's drug page


2. Bijuva

Bijuva is protected by 24 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10052386 Progesterone formulations 21 Nov, 2032
(8 years from now)
Active
US10206932 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US10639375 Progesterone formulations 21 Nov, 2032
(8 years from now)
Active
US10675288 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US10806740 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11033626 Progesterone formulations having a desirable pk profile 21 Nov, 2032
(8 years from now)
Active
US11103513 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11103516 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11110099 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11166963 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11529360 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11793819 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US11865179 Progesterone formulations having a desirable PK profile 21 Nov, 2032
(8 years from now)
Active
US8633178 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US8846648 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US8846649 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US8933059 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US8987237 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US8993548 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US8993549 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US9006222 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US9114145 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US9114146 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active
US9301920 Natural combination hormone replacement formulations and therapies 21 Nov, 2032
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bijuva's drug page


3. Doryx

Doryx is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8715724 Tabletting process 03 Feb, 2028
(3 years from now)
Active
US6958161 Modified release coated drug preparation 15 Dec, 2022
(1 year, 11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Doryx's drug page


4. Doryx Mpc

Doryx Mpc is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9446057 Controlled release doxycycline 23 Dec, 2034
(10 years from now)
Active
US9295652 Controlled release doxycycline 23 Oct, 2034
(9 years from now)
Active
US9511031 Controlled release doxycycline 23 Oct, 2034
(9 years from now)
Active
US8715724 Tabletting process 03 Feb, 2028
(3 years from now)
Active
US6958161 Modified release coated drug preparation 15 Dec, 2022
(1 year, 11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Doryx Mpc's drug page


5. Fabior

Fabior is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10568859 Topical foam composition 24 Feb, 2030
(5 years from now)
Active
US10688071 Topical foam composition 24 Feb, 2030
(5 years from now)
Active
US8808716 Topical foam composition 24 Feb, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fabior's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Imvexxy

Imvexxy is protected by 20 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11266661 Vaginal inserted estradiol pharmaceutical compositions and methods 02 Feb, 2034
(9 years from now)
Active
US10258630 Vaginal inserted estradiol pharmaceutical compositions and methods 20 Dec, 2033
(9 years from now)
Active
US10398708 Vaginal inserted estradiol pharmaceutical compositions and methods 20 Dec, 2033
(9 years from now)
Active
US9180091 Soluble estradiol capsule for vaginal insertion 20 Dec, 2033
(9 years from now)
Active
US10471072 Vaginal inserted estradiol pharmaceutical compositions and methods 18 Jun, 2033
(8 years from now)
Active
US10568891 Vaginal inserted estradiol pharmaceutical compositions and methods 18 Jun, 2033
(8 years from now)
Active
US10668082 Vaginal inserted estradiol pharmaceutical compositions and methods 18 Jun, 2033
(8 years from now)
Active
US10888516 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
(8 years from now)
Active
US11065197 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
(8 years from now)
Active
US11116717 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
(8 years from now)
Active
US11123283 Soluble estradiol capsule for vaginal insertion 18 Jun, 2033
(8 years from now)
Active
US10537581 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US10806697 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US10835487 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US11241445 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US11246875 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US11304959 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US11351182 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US11497709 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active
US9289382 Vaginal inserted estradiol pharmaceutical compositions and methods 21 Nov, 2032
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Imvexxy's drug page


7. Lexette

Lexette is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10857159
(Pediatric)
Halobetasol foam composition and method of use thereof 30 May, 2037
(12 years from now)
Active
US10857159 Halobetasol foam composition and method of use thereof 30 Nov, 2036
(12 years from now)
Active
US11020407 Corticosteroid containing foam compositions and method of manufacture thereof 30 Nov, 2036
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexette's drug page


8. Nextstellis

Nextstellis is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793760 Orodispersible dosage unit containing an estetrol component 17 Jun, 2036
(11 years from now)
Active
US11957694 Orodispersible dosage unit containing an estetrol component 17 Jun, 2036
(11 years from now)
Active
US11964055 Orodispersible dosage unit containing an estetrol component 17 Jun, 2036
(11 years from now)
Active
US7732430 Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception 02 Mar, 2025
(3 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nextstellis's drug page


9. Rhofade

Rhofade is protected by 8 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10335391 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
(10 years from now)
Active
US10751325 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
(10 years from now)
Active
US11517560 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
(10 years from now)
Active
US9974773 Stabilized oxymetazoline formulations and their uses 11 Jun, 2035
(10 years from now)
Active
US8883838 Pharmaceutical cream compositions and methods of use 01 Dec, 2031
(7 years from now)
Active
US7812049 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists 02 May, 2028
(3 years from now)
Active
US8420688 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists 02 Aug, 2024
(3 months ago)
Expired
US8815929 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists 22 Jan, 2024
(9 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rhofade's drug page


10. Sorilux

Sorilux is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8263580 Vitamin formulation 07 May, 2028
(3 years from now)
Active
US8269128 Vacuum switch tube 26 May, 2026
(1 year, 6 months from now)
Active
US8629128 Vitamin formulation 26 May, 2026
(1 year, 6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sorilux's drug page


11. Tolsura

Tolsura is protected by 6 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10463740 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
(8 years from now)
Active
US10806792 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
(8 years from now)
Active
US8921374 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
(8 years from now)
Active
US9272046 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
(8 years from now)
Active
US9713642 Itraconazole compositions and dosage forms, and methods of using the same 21 Jun, 2033
(8 years from now)
Active
US8771739 Pharmaceutical compositions for poorly soluble drugs 25 Jul, 2023
(1 year, 3 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tolsura's drug page


Mayne Pharma News

Anticipated in Dr Reddy's Q4: Consistent quarter expected with US sales and contribution from Revlimid

06 May, 2024

See More